EP Patent

EP1165135A1 — Methods of screening for compounds modulating fxr receptors

Assigned to City of Hope · Expires 2002-01-02 · 24y expired

What this patent protects

The present invention relates to methods and compositions for modulating genes which are controlled by the FXR orphan nuclear hormone receptor. In a preferred embodiment, the method involves modulation of the gene encoding Cyp7a, the enzyme responsible for a major pathway in the …

USPTO Abstract

The present invention relates to methods and compositions for modulating genes which are controlled by the FXR orphan nuclear hormone receptor. In a preferred embodiment, the method involves modulation of the gene encoding Cyp7a, the enzyme responsible for a major pathway in the elimination of cholesterol. The invention also relates to methods for screening compounds which bind to and activate or inhibit the FXR nuclear hormone receptor.

Drugs covered by this patent

Patent Metadata

Patent number
EP1165135A1
Jurisdiction
EP
Classification
—
Expires
2002-01-02
Drug substance claim
No
Drug product claim
No
Assignee
City of Hope
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.